Researchers have found in a new research that deucravacitinib significantly improves joint pain and musculoskeletal symptoms ...

From eczema and psoriasis to arthritis and Parkinson’s, the appearance of our hands can tell us a lot about the state of our ...

A new study from scientists at Scripps Research suggests that a drug already approved by the FDA to treat inflammation could help people with alcohol use disorder (AUD) by reducing both alcohol ...

Understand how psoriatic arthritis increases heart disease risk through inflammation. Learn management tips for heart health, from lifestyle changes to medication discussions.

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

Patients with rheumatoid and psoriatic arthritis maintained stable disease activity and functional capacity, with even some ...

Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

Submission is supported by 24-week results from the Phase 3b APEX study in adults with active psoriatic arthritis treated ...

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

Tumor necrosis factor inhibitor use in patients with IMIDs did not increase the risk of de novo heart failure or worsen existing heart failure.

Broc Shot is the first supplement to earn the Seal of Recognition from the National Psoriasis Foundation (NPF). This recognition highlights Broc Shot’s support for skin health from within, offering a ...

If you have brittle nails, swollen hands or unusually pale fingertips it may be more than just a damper to your manicure. It ...